Grants for For profit organizations other than small businesses - Federal

This grant seeks innovative proposals from a wide range of organizations, including universities and small businesses, to develop advanced technologies that enhance national defense capabilities.

The "Individually Measured Phenotypes to Advance Computational Translation in Mental Health (IMPACT-MH)" grant aims to support research that develops new behavioral measures and data infrastructure to improve the diagnosis, prognosis, and treatment of mental disorders.

This notice announces the opportunity to apply for funding under the Delta Region Maternal Care Coordination Program (Delta MCC). The purpose of this program is to improve and increase access to care for pregnant women and new mothers during and after pregnancy. To support this purpose, the objectives for the Delta MCC are to: 1. Use care coordination strategies to enhance and expand access to perinatal services in the Delta Region through a strong, diverse network of entities that represent the spectrum of care during and after pregnancy; 2. Utilize evidence-based, promising practices and/or value-based care model(s) in the planning and delivery of perinatal services; 3. Identify barriers to providing maternal health care in the region and strategies for addressing such barriers; and 4. Develop and implement deliberate and sustainable strategies of care coordination into policies, procedures, staffing, services, and communication systems (including but not limited to billing for appropriate services and partnering private and public payers). Applicants are encouraged to consider innovative strategies to meet the needs of and support pregnant women and new mothers. Some examples of activities that can be provided include: Provide outreach and education to pregnant women and new mothers on healthy nutrition to reduce risk of hypertension Provide screening and referral of mental health issues such as depression and anxiety including HRSAs Maternal Mental Health Hotline (1-833-TLC-MAMA) Refer pregnant women and new mothers to online or local support groups Recruitment of doula and midwifery services, community health workers, and/or maternal fetal specialist services Support patient care through telehealth Support travel costs, as necessary, of maternal health specialist to travel to pregnant woman Provide education and social support for pregnant women through the development of centering pregnancy (group prenatal care) visits; Provide resources and education to support in-home hypertension management and blood pressure self-monitoring and reporting; Support mobile prenatal and postpartum care visits for pregnant women and new mothers; Utilize development dyad models (mother and infant) to support combined postpartum and infant checkup visits; Support childcare for pregnant women and new mothers during prenatal and postpartum care visits; Applicants are encouraged to consider innovative strategies. Applicants are encouraged to propose ways to achieve these goals through the establishment or continuation of collaborative networks/consortiums of providers and services who support pregnant women and new mothers through pregnancy and post-partum. The networks will focus on reducing risk factors for pregnant women during and after pregnancy through screening and referral to needed services and interventions. HRSA recommends your members consist of a broad array of organizations from both traditional and non-traditional health care entities. Network members may include cross-sector entities such as health care providers, key services for supporting infant and child health, quality program providers, and insurers. See Appendix B for examples of the types of network members. This program funding should be used to complement the work of other organizations and should not duplicate or supplant activities that are funded through other federal mechanisms. The Delta MCC is a four-year program with year one (September 30, 2024 September 29, 2025) a planning year and years two, three, and four (September 30, 2025 September 29, 2028) focused on program implementation. For more details, see Program Requirements and Expectations.

This grant provides funding to early-career researchers focused on melanoma to support their independent research and professional development while fostering collaboration within a network of experts.

This grant provides funding for research aimed at developing new therapies for amyotrophic lateral sclerosis (ALS), specifically targeting projects that have already shown promise in preclinical studies and emphasize the use of biomarkers for therapeutic development.

This grant provides funding for U.S.-based research institutions to develop applications and technologies using advanced radar data from a collaborative NASA and ISRO mission, focusing on monitoring Earth's land and ice changes.

This funding opportunity provides financial support to community organizations and public agencies to develop and implement programs that prevent adult suicide and promote mental health resilience through collaborative, non-clinical approaches.

The MBRP TTDA is a product-driven award mechanism intended to provide support for the translation of promising preclinical findings into products for clinical application in resource-limited settings, particularly within the pre-hospital, or early, acute phase of care environments. Applications must address one or more of the critical gaps included in the FY24 MBRP TTDA Focus Areas. Products under development must address the needs of military Service Members, Veterans, their beneficiaries, and the American public.The product(s) to be developed may be a tangible item such as a medical device or pharmacologic agent (including, but not limited to, drugs or biologics). Knowledge products may be considered, provided that the knowledge is applicable to a technology or therapeutic under development. (A knowledge product is a non-materiel product that addresses an identified need in one or more of the FY24 MBRP TTDA Focus Areas. A knowledge product is based on current evidence, aims to transition clinical practice standards, training, or tools into clinical practice, or supports materiel solutions [systems to develop, acquire, provide, and sustain medical solutions and capabilities], and educates or impacts behavior throughout the continuum of care, including primary prevention of negative outcomes.)At the time of pre-application submission the proposed product must have achieved a minimum technology readiness level (TRL) or knowledge readiness level (KRL) of 3 (Appendix II).Proof-of-concept AND a prototype/preliminary version of the proposed product demonstrating its potential utility must be established at the time of pre-application submission. Applications must include relevant data that support the rationale for the proposed study. These data may be unpublished and/or from the published literature.This award mechanism is intended to facilitate progression of research that is supported by significant preliminary data but has not yet advanced to the level of clinical use. Examples of the types of research that may be supported include, but are not limited to: Testing new therapeutic or technologic modalities (e.g., agents, delivery systems, chemical modification of lead compounds, device testing and/or validation) using established or validated preclinical systems Designing pilot or full-scale Good Manufacturing Practice (GMP) production of therapeutics and/or technologies for use in advanced preclinical studies Developing pharmacologic agents through absorption, distribution, metabolism, excretion, and toxicity studies Investigational New Drug- or Investigational Device Exemption-enabling studiesClinical trials and clinical research studies ARE NOT PERMITTED under this award mechanism. Projects involving limited use of commercially available human cells or anatomical specimens are permitted, provided that the use of such specimens is necessary for device or product development. Applicants interested in proposing clinical research should consider submitting to the FY24 MBRP Patient-Centered Research Award mechanism (HT942524MBRPPCRA).A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.Impact: The overall impact of the proposed research is a key component of this award mechanism. High-impact research will, if successful, lead to the development and translation of therapeutic or technologic advances for clinical application in the care of burn-injured casualties, such as detection, diagnosis, treatment, or burn complication prevention.Relevance to Military Health: Relevance to the health care needs of burn-injured military Service Members is a key feature of this award.Use of DOD or Department of Veterans Affairs (VA) Resources: Applications involving multidisciplinary collaborations among academia, industry, the military Services, the VA, and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Applicants are encouraged to integrate and/or align their research projects with DOD and/or VA research laboratories and programs. Collaboration with DOD or VA investigators is also encouraged. A list of websites that may be useful in identifying additional information about ongoing DOD and VA areas of research interest or potential opportunities for collaboration can be found in Appendix IV.Rigor of Experimental Design: All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies. Projects that include research on animal models are required to submit Attachment 8, Animal Research Plan, as part of the application package to describe how these standards will be addressed. Applicants should consult the ARRIVE guidelines 2.0 (Animal Research: Reporting In Vivo Experiments) to ensure relevant aspects of rigorous animal research are adequately planned for and, ultimately, reported. The ARRIVE guidelines 2.0 can be found at https://arriveguidelines.org/arrive-guidelines.The CDMRP expects to allot approximately $4.4M to fund approximately two MBRP Technology/Therapeutic Development Award applications. Funding of applications received is contingent upon the availability of federal funds for this program as well as the number of applications received, the quality and merit of the applications as evaluated by scientific and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.The funding instrument for awards made under the program announcement will be assistance agreements, contracts, or Other Transactions. The type of instrument used to reflect the business relationship between the organization and the government is at the discretion of the government, in accordance with the Federal Grant and Cooperative Agreement Act of 1977, as amended, 31 USC 6301-6308, which provides the legal criteria to select a procurement contract or an assistance agreement. The USAMRDC will also consider the use of Other Transactions (OTs) as a vehicle for award, in accordance with the conditions in 10 USC 4021 and 10 USC 4022.An assistance agreement can take the form of a grant or cooperative agreement. The level of government involvement during the projects period of performance is the key factor in determining whether to award a grant or cooperative agreement. If no substantial government involvement is anticipated, a grant will be made (31 USC 6304). Conversely, if substantial government involvement is anticipated, a cooperative agreement will be made (31 USC 6305). Substantial involvement means that members of the U.S. government will assist, guide, coordinate, or participate in project activities.A contract is required when the principal purpose of the instrument is to acquire property or services for the direct benefit or use of the U.S. government.An Other Transaction will also be considered as a vehicle for award under this BAA, in accordance with 10 USC 4021 and 10 USC 4022. The OT authorities were created to give DOD the flexibility necessary to adopt and incorporate business practices that reflect commercial industry standards and best practices into its award instruments. When leveraged appropriately, OTs provide the government with access to state-of-the-art technology solutions from traditional and non-traditional defense contractors (NDCs), through a multitude of potential teaming arrangements tailored to the particular project and the needs of the participants. OTs can help to foster new relationships and practices involving traditional and NDCs, especially those that may not be interested in entering into FAR-based contracts with the government; broaden the industrial base available to government; support dual-use projects; encourage flexible, quicker, and cheaper project design and execution; leverage commercial industry investment in technology development and partner with industry to ensure DOD requirements are incorporated into future technologies and products; and collaborate in innovative arrangements. OTs are not FAR-based procurement contracts, grants, cooperative agreements, or cooperative research and development agreements.The award type, along with the start date, will be determined during the negotiation process.The anticipated total costs budgeted for the entire period of performance for an FY24 MBRP Technology/Therapeutic Development Award should not exceed $2.2M. Refer to Section II.D.6, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025. For additional information refer to Section II.F.1, Federal Award Notices.

The National Institute on Aging is offering a grant for graduate students interested in aging-related research, providing funding and support for their doctoral dissertation projects and transition into postdoctoral positions in the field.

This grant provides funding for innovative projects that develop new, powerful magnetic materials to improve energy efficiency and reduce reliance on rare earth resources, targeting a wide range of applicants including universities, nonprofits, and businesses.

This funding opportunity provides financial support for faculty and students at under-resourced academic institutions to collaborate with NASA on research projects, fostering mentorship and skill development in STEM fields.

This initiative provides up to $10 million in prizes to innovators developing advanced LED lighting solutions that improve energy efficiency, quality, and accessibility for commercial use.

This funding opportunity provides financial support to organizations working to strengthen small and medium-sized enterprises in Haiti, helping them improve performance, access financing, and create jobs to foster economic growth.

The purpose of this program is to strengthen the behavioral health workforce in rural Northern Border Regional Commission (NBRC) service areas through supporting the recruitment and retention of behavioral health care providers.

This funding opportunity supports small U.S.-based businesses in developing and scaling innovative therapies using extracellular vesicles for regenerative medicine applications, such as tissue and organ repair.

This funding opportunity supports a wide range of research and technology development in Earth and space sciences, aimed at U.S.-based institutions, nonprofits, private entities, and government organizations, to advance NASA's strategic mission goals.

This funding opportunity provides financial support to nonprofit organizations and other eligible entities to enhance the documentation and accountability of religious freedom abuses in Nigeria, focusing on improving data collection and advocacy efforts in areas affected by religious violence.

This funding opportunity provides financial support to nonprofit organizations, educational institutions, and for-profit entities to empower local communities in Sudan to detect and respond to early signs of violence, promoting peace and security in the region.

This funding opportunity supports collaborative cancer research projects that integrate multiple studies to advance knowledge in cancer biology, prevention, diagnosis, treatment, and control, targeting a wide range of eligible institutions and organizations.

This funding opportunity supports organizations in developing training and outreach initiatives to enhance the use of pediatric research data, focusing on childhood cancer and congenital anomalies.